questionsmedicales.fr
États, signes et symptômes pathologiques
Signes et symptômes
Signes et symptômes digestifs
Hyperphagie
Hyperphagie : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Hyperphagie
Troubles de l'alimentation
Évaluation psychologique
Nutrition
Trouble de l'hyperphagie boulimique
DSM-5
Symptômes
5
Symptômes
Troubles de l'alimentation
Douleur abdominale
Hyperphagie
Diabète de type 2
Troubles métaboliques
Prévention
5
Éducation nutritionnelle
Gestion du stress
Soutien social
Troubles alimentaires
Sensibilisation
Prévention
Exercice physique
Comportements alimentaires
Méditation
Gestion du stress
Traitements
5
Thérapie comportementale
Médicaments
Thérapie cognitive
Comportement alimentaire
Soutien nutritionnel
Habitudes alimentaires
Hospitalisation
Traitement intensif
Complications
5
Maladies cardiovasculaires
Obésité
Reflux gastro-œsophagien
Douleurs abdominales
Troubles du sommeil
Inconfort physique
Facteurs de risque
5
Antécédents familiaux
Stress
Stress
Troubles alimentaires
Antécédents de troubles alimentaires
Hyperphagie
Isolement social
Comportements alimentaires
Changements hormonaux
Appétit
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperphagie : Questions médicales les plus fréquentes",
"headline": "Hyperphagie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperphagie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-28",
"dateModified": "2025-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperphagie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Signes et symptômes digestifs",
"url": "https://questionsmedicales.fr/mesh/D012817",
"about": {
"@type": "MedicalCondition",
"name": "Signes et symptômes digestifs",
"code": {
"@type": "MedicalCode",
"code": "D012817",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.821"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Boulimie",
"alternateName": "Bulimia",
"url": "https://questionsmedicales.fr/mesh/D002032",
"about": {
"@type": "MedicalCondition",
"name": "Boulimie",
"code": {
"@type": "MedicalCode",
"code": "D002032",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.821.645.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperphagie",
"alternateName": "Hyperphagia",
"code": {
"@type": "MedicalCode",
"code": "D006963",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andrea M Haqq",
"url": "https://questionsmedicales.fr/author/Andrea%20M%20Haqq",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of Alberta, 8440 - 112 St NW, Edmonton, AB, T6G 2B7, Canada. haqq@ualberta.ca."
}
},
{
"@type": "Person",
"name": "Arashdeep Singh",
"url": "https://questionsmedicales.fr/author/Arashdeep%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacodynamics, Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, FL, USA."
}
},
{
"@type": "Person",
"name": "Julia von Schnurbein",
"url": "https://questionsmedicales.fr/author/Julia%20von%20Schnurbein",
"affiliation": {
"@type": "Organization",
"name": "Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany."
}
},
{
"@type": "Person",
"name": "Martin Wabitsch",
"url": "https://questionsmedicales.fr/author/Martin%20Wabitsch",
"affiliation": {
"@type": "Organization",
"name": "Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany. Electronic address: Martin.Wabitsch@uniklinik-ulm.de."
}
},
{
"@type": "Person",
"name": "Usha G Mallya",
"url": "https://questionsmedicales.fr/author/Usha%20G%20Mallya",
"affiliation": {
"@type": "Organization",
"name": "Rhythm Pharmaceuticals, Inc., Boston, MA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36580184",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10147-022-02288-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.",
"datePublished": "2022-08-02",
"url": "https://questionsmedicales.fr/article/35918785",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1515/cclm-2022-0506"
}
},
{
"@type": "ScholarlyArticle",
"name": "Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36171391",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-20319-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Autocrine amphiregulin signaling sustains castration-resistant Ly6d",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37331831",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tcb.2023.05.011"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Molecular signatures in castration-resistant prostate cancers: An update].",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35871861",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bulcan.2022.06.007"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Signes et symptômes digestifs",
"item": "https://questionsmedicales.fr/mesh/D012817"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hyperphagie",
"item": "https://questionsmedicales.fr/mesh/D006963"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperphagie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperphagie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperphagie",
"description": "Comment diagnostiquer l'hyperphagie ?\nQuels tests sont utilisés pour l'hyperphagie ?\nL'hyperphagie est-elle liée à d'autres troubles ?\nQuels critères DSM sont utilisés pour l'hyperphagie ?\nL'hyperphagie peut-elle être confondue avec d'autres troubles ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperphagie",
"description": "Quels sont les symptômes de l'hyperphagie ?\nL'hyperphagie provoque-t-elle des douleurs ?\nY a-t-il des signes psychologiques associés ?\nComment l'hyperphagie affecte-t-elle le poids ?\nL'hyperphagie peut-elle causer des troubles métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperphagie",
"description": "Comment prévenir l'hyperphagie ?\nLe soutien social aide-t-il à prévenir l'hyperphagie ?\nLes programmes de sensibilisation sont-ils efficaces ?\nL'exercice physique aide-t-il à prévenir l'hyperphagie ?\nLes techniques de relaxation sont-elles utiles ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperphagie",
"description": "Quels traitements sont disponibles pour l'hyperphagie ?\nLa thérapie cognitive est-elle efficace ?\nDes médicaments sont-ils prescrits pour l'hyperphagie ?\nLe soutien nutritionnel est-il important ?\nL'hyperphagie nécessite-t-elle une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperphagie",
"description": "Quelles complications peuvent survenir avec l'hyperphagie ?\nL'hyperphagie peut-elle affecter la santé mentale ?\nY a-t-il des risques de maladies cardiovasculaires ?\nDes problèmes digestifs peuvent-ils survenir ?\nL'hyperphagie peut-elle entraîner des troubles du sommeil ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperphagie",
"description": "Quels sont les facteurs de risque de l'hyperphagie ?\nLe stress est-il un facteur de risque ?\nLes antécédents de troubles alimentaires augmentent-ils le risque ?\nL'isolement social est-il un facteur de risque ?\nLes changements hormonaux influencent-ils l'hyperphagie ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Castration#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperphagie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des habitudes alimentaires et des symptômes associés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'hyperphagie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucun test spécifique, mais des évaluations psychologiques et nutritionnelles peuvent être effectuées."
}
},
{
"@type": "Question",
"name": "L'hyperphagie est-elle liée à d'autres troubles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut coexister avec des troubles comme l'anxiété ou la dépression."
}
},
{
"@type": "Question",
"name": "Quels critères DSM sont utilisés pour l'hyperphagie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le DSM-5 définit des critères spécifiques pour le trouble de l'hyperphagie boulimique."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle être confondue avec d'autres troubles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec la boulimie ou l'orthorexie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hyperphagie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une consommation excessive de nourriture, des sentiments de honte et de culpabilité."
}
},
{
"@type": "Question",
"name": "L'hyperphagie provoque-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des douleurs abdominales dues à une suralimentation fréquente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes psychologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme l'anxiété, la dépression et une faible estime de soi sont fréquents."
}
},
{
"@type": "Question",
"name": "Comment l'hyperphagie affecte-t-elle le poids ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une prise de poids significative et des problèmes de santé associés."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle causer des troubles métaboliques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut contribuer à des troubles métaboliques comme le diabète de type 2."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperphagie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une éducation nutritionnelle et la gestion du stress."
}
},
{
"@type": "Question",
"name": "Le soutien social aide-t-il à prévenir l'hyperphagie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon soutien social peut réduire le risque de développer des troubles alimentaires."
}
},
{
"@type": "Question",
"name": "Les programmes de sensibilisation sont-ils efficaces ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les programmes de sensibilisation peuvent aider à identifier et à traiter les problèmes tôt."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir l'hyperphagie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer l'humeur et réduire les comportements alimentaires compulsifs."
}
},
{
"@type": "Question",
"name": "Les techniques de relaxation sont-elles utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la méditation peuvent aider à gérer le stress et les envies alimentaires."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hyperphagie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie comportementale, la médication et le soutien nutritionnel."
}
},
{
"@type": "Question",
"name": "La thérapie cognitive est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie cognitive peut aider à modifier les comportements alimentaires et les pensées."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits pour l'hyperphagie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antidépresseurs et des médicaments anti-anxiété peuvent être prescrits pour aider."
}
},
{
"@type": "Question",
"name": "Le soutien nutritionnel est-il important ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien nutritionnel aide à établir des habitudes alimentaires saines."
}
},
{
"@type": "Question",
"name": "L'hyperphagie nécessite-t-elle une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans les cas graves, une hospitalisation peut être nécessaire pour un traitement intensif."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hyperphagie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obésité, le diabète, et des problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle affecter la santé mentale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des troubles mentaux comme la dépression et l'anxiété."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hyperphagie augmente le risque de maladies cardiovasculaires en raison de l'obésité."
}
},
{
"@type": "Question",
"name": "Des problèmes digestifs peuvent-ils survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes comme le reflux gastro-œsophagien et des douleurs abdominales peuvent se produire."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle entraîner des troubles du sommeil ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut causer des troubles du sommeil en raison de l'inconfort physique et psychologique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hyperphagie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles mentaux et des événements stressants."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress émotionnel peut déclencher des épisodes d'hyperphagie chez certaines personnes."
}
},
{
"@type": "Question",
"name": "Les antécédents de troubles alimentaires augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents de troubles alimentaires augmente le risque d'hyperphagie."
}
},
{
"@type": "Question",
"name": "L'isolement social est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'isolement social peut contribuer à des comportements alimentaires désordonnés."
}
},
{
"@type": "Question",
"name": "Les changements hormonaux influencent-ils l'hyperphagie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements hormonaux, comme ceux liés à la grossesse, peuvent affecter l'appétit."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, University of Alberta, 8440 - 112 St NW, Edmonton, AB, T6G 2B7, Canada. haqq@ualberta.ca.
Publications dans "Hyperphagie" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, FL, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany. Electronic address: Martin.Wabitsch@uniklinik-ulm.de.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Rhythm Pharmaceuticals, Inc., Boston, MA, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Center for Hypothalamic Research, Departments of Internal Medicine and Neuroscience, Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Center for Hypothalamic Research, Departments of Internal Medicine and Neuroscience, Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Vanderbilt University Medical Center, Nashville, Tennessee.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Case Western Reserve University, Cleveland, Ohio.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
The John B. Pierce Laboratory, New Haven, CT, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, FL, USA; The John B. Pierce Laboratory, New Haven, CT, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, FL, USA; The John B. Pierce Laboratory, New Haven, CT, USA; Yale University, New Haven, CT, USA. Electronic address: gdelartigue@ufl.edu.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics University of Florida College of Medicine Gainesville Florida USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Psychology, Vanderbilt University, Nashville, Tennessee, USA.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Foundation for Prader-Willi Research, Walnut, California, United States of America.
PWS-Clinical Trial Consortium, Walnut, California, United States of America.
Department of Genetics, University of Alabama, Birmingham, Alabama, United States of America.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Foundation for Prader-Willi Research, Walnut, California, United States of America.
PWS-Clinical Trial Consortium, Walnut, California, United States of America.
Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, United States of America.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Sağlik Bilimleri University, Tepecik Training and Research Hospital, İzmir, Turkey.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Nutrition and Dietetics, Sağlik Bilimleri University, Tepecik Training and Research Hospital, İzmir, Turkey.
Publications dans "Hyperphagie" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokuz Eylül University, Faculty of Medicine, İzmir, Turkey.
Publications dans "Hyperphagie" :
Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who rece...
We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA-progression-f...
PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with...
Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA-PFS....
Testosterone testing is relevant for evaluating castration adequacy and diagnosis of castration-resistant prostate cancer (PCa). However, the recommended testosterone cut-off of 1.7 nmol/L (50 ng/dL) ...
Leftover serum from 120 PCa patients castrated with luteinizing hormone-releasing hormone agonists was analysed for testosterone by five methods: Architect i2000 (Abbott), Access (Beckman), Cobas 6000...
All castration upper limits, ranging from 0.472 nmol/L (LC-MS/MS) to 1.25 nmol/L (Access) (95% percentile), were significantly lower than the current castration cut-off (1.7 nmol/L). Slopes of Passing...
These results suggest that a lower general testosterone castration cut-off may be more appropriate in evaluating the adequacy of castration in PCa and that present-day AIA lack analytical accuracy to ...
We aimed to identify prognostic factors of cancer-specific survival (CSS) in non-metastatic castration-resistant prostate cancer (M0CRPC) patients. The final analysis of this retrospective cohort incl...
Mechanisms underlying the development of castration-resistant prostate cancer (CRPC) remain incompletely understood. A recent study by Steiner et al. shows that Ly6d...
Castration resistant prostate cancers are highly heterogenous at the molecular level. With the use of new generation sequencing technologies, a series of alterations were identified, opening the way f...
WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique st...
We performed an international multi-institutional retrospective study of 277 men with metachronous omCSPC who underwent targeted DNA sequencing of their primary/metastatic tumor. Patients were classif...
A pathogenic WNT pathway mutation was detected in 11.2% of patients. Patients with WNT pathway mutations were more likely to have visceral metastases (22.6% vs 2.8%; P < .01) and less likely to have r...
Somatic WNT pathway alterations are present in approximately 11% of patients with omCSPC and are associated with an increased likelihood of visceral metastases. Although these patients have a worse na...
Myocardial bridge is a morphological anomaly of the heart characterised by the presence of a myocardial segment above a coronary artery, which results in a higher risk of cardiovascular events. In pat...
An 88 years old man with metastatic castration-resistant prostate cancer in treatment with enzalutamide, denosumab, and triptorelin presented to our attention complaining dyspnoea and angina pectoris....
Blood examinations revealed normal Troponin I levels. Transthoracic echocardiography revealed no signs of acute myocardial ischaemia. The treadmill stress test revealed S-T tract under levelling in V4...
Due to the high prevalence of prostate cancer in elderly patients at high cardiovascular risk and the increasing use of androgen receptor-targeted agent, a multidisciplinary approach is highly recomme...
Patients with mCSPC experience a longer overall survival with treatment intensification by addition of novel hormonal therapy (NHT) or docetaxel to androgen deprivation vs androgen deprivation alone. ...
Reports on first line (1L) treatment patterns were obtained for years 2015 to 2021. Medicaid, Medicare, Medicare part D, cash transactions, and commercial data were included for years 2012 to 2021....
Nationwide, of 66,844 men with newly diagnosed mCSPC since 2015, on average 25% were prescribed NHT, and another 12% were prescribed chemotherapy. No differences were noted in treatment patterns based...
Both medical oncology and urology providers need to improve their treatment intensification efforts for men with mCSPC to increase their patients' overall survival....
The treatment of castration-sensitive prostate cancer (CSPC) has been revolutionized by the advent of apalutamide and enzalutamide in this setting; however, a direct comparison between these agents is...
The clinical significance of bone marrow (BM) metastasis in prostate cancer as well as impact on oncological prognosis is unclear. We aim to assess the prevalence and clinical outcomes of BM metastasi...
Retrospective chart review of newly diagnosed metastatic CSPC patients was performed with collection of clinicopathologic and radiologic characteristics. Descriptive univariate and multivariate analys...
189 patients were eligible, of which, eleven patients (6%) had biopsy proven BM involvement at diagnosis. There was a trend to poorer PFS and OS in patients with BM involvement but not statistically s...
BM metastasis in prostate cancer may lead to poorer survival. Clinical features including poor performance status, anemia, and elevated ALP, could guide bone marrow biopsies in the future to diagnose ...